What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2).

What question did this study set out to answer?

To evaluate the efficacy and safety of total neoadjuvant therapy with PD-L1 blockade in locally advanced rectal cancer patients.

March 14, 2026International Journal of Surgery0 citationsOpen Access

Efficacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in PMMR/MSS locally advanced rectal cancer (ESTIMATE): an open-label, prospective, phase II trial

View Full Paper

XZXi ZhangGeneral Cardiology TWT.‐C. WuChang Gung University QFQing FengKunming Medical University

Key Points

To evaluate the efficacy and safety of total neoadjuvant therapy with PD-L1 blockade in locally advanced rectal cancer patients.
Open-label, prospective phase II trial
Patients received mFOLFOX6, envafolimab, and chemoradiation
Assessment included clinical response and follow-up for adverse events
51.5% complete response rate with potential organ preservation
38.5% pathological complete response post-surgery
Adverse events observed in 87.9% of patients, predominantly mild

Abstract

Purpose: Although total neoadjuvant therapy (TNT) improves outcomes in locally advanced rectal cancer (LARC), patients with proficient mismatch repair (pMMR)/microsatellite stability (MSS) tumors respond poorly to conventional regimens. Patients and Methods: This phase II trial (ESTIMATE) evaluated a novel TNT protocol integrating PD-L1 blockade (envafolimab) in 33 pMMR/MSS LARC patients with tumors located ≤10 cm from the anal verge. The regimen comprised: induction with mFOLFOX6 plus subcutaneous envafolimab (200 mg q2w × 2 cycles), concurrent chemoradiation (50 Gy/25 fractions with capecitabine 825 mg/m 2 plus envafolimab q2w × 3 cycles), and consolidation with mFOLFOX6/Envafolimab ×2 cycles. Patients achieving a clinical complete response (cCR) with undetectable circulating tumor DNA (ctDNA) can opt for watch-and-wait (W&W). Results: The complete response (CR) rate, which integrates pathological complete response (pCR) and cCR, reached 51.5% (17/33), with 21.2% (7/33) achieving organ preservation. Pathological assessment revealed 38.5% pCR (10/26) and 73.1% major response (19/26) after total mesorectal excision (TME). Transcriptomic profiling identified UBD overexpression and RPL21 downregulation as predictive biomarkers. Adverse events occurred in 87.9% (29/33) of the patients, predominantly grade 1–2. Grade 3 neutropenia occurred in 9.1% (3/33) of the patients, and injection-site reaction occurred in 1 patient (3%). With a median follow-up of 27 months (IQR 25-29), the 2-year DFS and OS rates were 90.9% (95% CI: 77.0%–97.6%) and 100% (95% CI: 90.1%–100%), respectively. Distant metastases developed in one of seven patients (14.3%) managed with W&W and two of 26 patients (7.7%) undergoing TME. Conclusions: PD-L1 blockade-enhanced TNT achieves encouraging efficacy, organ preservation, and acceptable tolerability in pMMR/MSS LARC, supported by mechanistically relevant biomarkers.

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper

Efficacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in PMMR/MSS locally advanced rectal cancer (ESTIMATE): an open-label, prospective, phase II trial

Key Points

Abstract

Cite This Study

Also Consider

Also Consider